Abstract
Objective
Craniopharyngiomas (CPG) have complex treatment challenges due to their proximity to vital structures, surgical and radiotherapeutic complexities, and the tendency for recurrence. The aim of this study was to identify the prevalence of endocrine and metabolic comorbidities observed during initial diagnosis and long-term follow-up in a nationwide cohort of pediatric CPG patients. A further aim was to highlight the difficulties associated with CPG management.
Methods
Sixteen centers entered CPG patients into the ÇEDD NET data system. The clinical and laboratory characteristics at presentation, administered treatments, accompanying endocrine, metabolic, and other system involvements, and the patient’s follow-up features were evaluated.
Results
Of the 152 evaluated patients, 64 (42.1%) were female. At presentation, the mean age was 9.1±3.67, ranging from 1.46 to 16.92, years. The most common complaints at presentation were headache (68.4%), vision problems (42%), short stature (15%), and nausea and vomiting (7%). The surgical procedures were gross total resection (GTR) in 97 (63.8%) and subtotal resection in 55 (36.2%). Radiotherapy (RT) was initiated in 11.8% of the patients. Histopathological examination reported 92% were adamantinamatous type and 8% were papillary type. Postoperatively, hormone abnormalities consisted of thyroid-stimulating hormone (92.1%), adrenocorticotropic hormone (81%), antidiuretic hormone (79%), growth hormone (65.1%), and gonadotropin (43.4%) deficiencies. Recombinant growth hormone treatment (rhGH) was initiated in 27 (17.8%). The study showed hesitancy among physicians regarding rhGH. The median survival without relapse was 2.2 years. Median (range) time of relapse was 1.82 (0.13-10.35) years. Relapse was related to longer follow-ups and reduced GTR rates. The median follow-up time was 3.13 years. Among the last follow-up visits, the prevalence of obesity was 38%, but of these, 46.5% were already obese at diagnosis. However, 20% who were not obese at baseline became obese on follow-up. Permanent visual impairment was observed in 26 (17.1%), neurological deficits in 13 (8.5%) and diabetes mellitus in 5 (3.3%) patients.
Conclusion
Recurrence was predominantly due to incomplete resection and the low rate of postoperative RT. Challenges emerged for multidisciplinary regular follow ups. It is suggested that early interventions, such as dietary restrictions and increased exercise to prevent obesity, be implemented.
Keywords: Craniopharyngioma, pituitary, dysfunction
Read the full text
5 sections · 2 tables · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Asirvatham JR, Deepti AN, Chyne R, Prasad MS, Chacko AG, Rajshekhar V, Chacko G. Pediatric tumors of the central nervous system: a retrospective study of 1,043 cases from a tertiary care center in South India. Childs Nerv Syst. 2011;27:1257-1263. Epub 2011 Feb 23
Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma. Nat Rev Dis Primers. 2019;5:75.
Müller HL, Merchant TE, Puget S, Martinez-Barbera JP. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol. 2017;13:299-312. Epub 2017 Feb 3
Enayet AER, Atteya MME, Taha H, Zaghloul MS, Refaat A, Maher E, Abdelaziz A, El Beltagy MA. Management of pediatric craniopharyngioma: 10-year experience from high-flow center. Childs Nerv Syst. 2021;37:391-401. Epub 2020 Jul 26
Lim MJR, Wee RGM, Aw NMY, Liu SJ, Ho CWL, Teo K, Lwin S, Yeo TT, Kimpo M, Nga VDW. Management and Outcomes of Pediatric Craniopharyngioma: A 15-Year Experience in Singapore. World Neurosurg. 2023;177:415-424.
Merchant TE, Dangda S, Hoehn ME, Wu S, Li Y, Wang F, Pan H, Boop FA, Jurbergs N, Conklin HM. Pediatric Craniopharyngioma: The Effect of Visual Deficits and Hormone Deficiencies on Long-Term Cognitive Outcomes After Conformal Photon Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023;115:581-591. Epub 2022 Sep 18
van Santen SS, Olsson DS, Hammarstrand C, Wijnen M, Fiocco M, van den Heuvel-Eibrink MM, Johannsson G, Janssen JAMJL, van der Lely AJ, Neggers SJCMM. Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. J Clin Endocrinol Metab. 2020;105:dgaa607.
Yano S, Kudo M, Hide T, Shinojima N, Makino K, Nakamura H, Kuratsu J. Quality of Life and Clinical Features of Long-Term Survivors Surgically Treated for Pediatric Craniopharyngioma. World Neurosurg. 2016;85:153-162. Epub 2015 Sep 1
Kendall-Taylor P, Jönsson PJ, Abs R, Erfurth EM, Koltowska-Häggström M, Price DA, Verhelst J. The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol. 2005;152:557-567.
Poretti A, Grotzer MA, Ribi K, Schönle E, Boltshauser E. Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol. 2004;46:220-229.
Müller HL, Bruhnken G, Emser A, Faldum A, Etavard-Gorris N, Gebhardt U, Kolb R, Sörensen N. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv Syst. 2005;21:975-980. Epub 2005 Jun 18
Dekkers OM, Biermasz NR, Smit JW, Groot LE, Roelfsema F, Romijn JA, Pereira AM. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol. 2006;154:483-489.
Müller HL. Childhood craniopharyngioma--current concepts in diagnosis, therapy and follow-up. Nat Rev Endocrinol. 2010;6:609-618. Epub 2010 Sep 28
Müller HL. The Diagnosis and Treatment of Craniopharyngioma. Neuroendocrinology. 2020;110:753-766. Epub 2019 Nov 4
Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer. 2008;51:110-117.
Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, Neelis KJ, Biermasz NR, Romijn JA, Smit JW, Pereira AM. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:2330-2340. Epub 2011 May 25
Follin C, Erfurth EM. Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors. Curr Treat Options Oncol. 2016;17:50.
Graffeo CS, Perry A, Link MJ, Daniels DJ. Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon. J Neurol Surg B Skull Base. 2018;79:65-80. Epub 2018 Jan 19
van Santen SS, Olsson DS, Hammarstrand C, Wijnen M, van den Heuvel-Eibrink MM, van der Lely AJ, Johannsson G, Janssen JAMJL, Neggers SJCMM. Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. Eur J Endocrinol. 2019;181:173-183.
Lustig RH. Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment. Front Endocrinol (Lausanne). 2011;2:60.
Beckhaus J, Friedrich C, Boekhoff S, Calaminus G, Bison B, Eveslage M, Timmermann B, Flitsch J, Müller HL. Outcome after pediatric craniopharyngioma: the role of age at diagnosis and hypothalamic damage. Eur J Endocrinol. 2023;188:300-309.
Agresta G, Campione A, Veiceschi P, Gallo D, Agosti E, Massimi L, Piatelli G, Consales A, Linsler S, Oertel J, Pozzi F, Tanda ML, Castelnuovo P, Locatelli D. Clinical and oncological outcomes in single-stage versus staged surgery for pediatric craniopharyngiomas: a multicenter retrospective study. J Endocrinol Invest. 2023;46:1219-1232. Epub 2022 Dec 22
Jazbinšek S, Kolenc D, Bošnjak R, Faganel Kotnik B, Zadravec Zaletel L, Jenko Bizjan B, Vipotnik Vesnaver T, Battelino T, Janež A, Jensterle M, Kotnik P. Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Craniopharyngioma. Horm Res Paediatr. 2020;93:46-57. Epub 2020 May 27
Price DA, Jönsson P. Effect of growth hormone treatment in children with craniopharyngioma with reference to the KIGS (Kabi International Growth Study) database. Acta Paediatr Suppl. 1996;417:83-85.
Nguyen Quoc A, Beccaria K, González Briceño L, Pinto G, Samara-Boustani D, Stoupa A, Beltrand J, Besançon A, Thalassinos C, Puget S, Blauwblomme T, Alapetite C, Bolle S, Doz F, Grill J, Dufour C, Bourdeaut F, Abbou S, Guerrini-Rousseau L, Leruste A, Brabant S, Cavadias I, Viaud M, Boddaert N, Polak M, Kariyawasam D. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy? J Clin Endocrinol Metab. 2023;108:1929-1936.
Alotaibi NM, Noormohamed N, Cote DJ, Alharthi S, Doucette J, Zaidi HA, Mekary RA, Smith TR. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis. World Neurosurg. 2018;109:487-496. Epub 2017 Oct 4
Price DA, Wilton P, Jönsson P, Albertsson-Wikland K, Chatelain P, Cutfield W, Ranke MB. Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996. Horm Res. 1998;49:91-97.
Boekhoff S, Bogusz A, Sterkenburg AS, Eveslage M, Müller HL. Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo). Eur J Endocrinol. 2018;179:331-341.
Heinks K, Boekhoff S, Hoffmann A, Warmuth-Metz M, Eveslage M, Peng J, Calaminus G, Müller HL. Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007. Endocrine. 2018;59:364-372. Epub 2017 Dec 11
Seckl JR, Dunger DB, Lightman SL. Neurohypophyseal peptide function during early postoperative diabetes insipidus. Brain. 1987;110:737-746.
Hannon MJ, Finucane FM, Sherlock M, Agha A, Thompson CJ. Clinical review: Disorders of water homeostasis in neurosurgical patients. J Clin Endocrinol Metab. 2012;97:1423-1433. Epub 2012 Feb 22
Drapeau A, Walz PC, Eide JG, Rugino AJ, Shaikhouni A, Mohyeldin A, Carrau RL, Prevedello DM. Pediatric craniopharyngioma. Childs Nerv Syst. 2019;35:2133-2145. Epub 2019 Aug 5
Liu AP, Tung JY, Ku DT, Luk CW, Ling AS, Kwong DL, Cheng KK, Ho WW, Shing MM, Chan GC. Outcome of Chinese children with craniopharyngioma: a 20-year population-based study by the Hong Kong Pediatric Hematology/Oncology Study Group. Childs Nerv Syst. 2020;36:497-505. Epub 2020 Jan 23
Sklar CA. Craniopharyngioma: endocrine sequelae of treatment. Pediatr Neurosurg. 1994;21(Suppl 1):120-123.
Nuijts MA, Veldhuis N, Stegeman I, van Santen HM, Porro GL, Imhof SM, Schouten-van Meeteren AYN. Visual functions in children with craniopharyngioma at diagnosis: A systematic review. PLoS One. 2020;15:e0240016.
Müller HL, Gebhardt U, Teske C, Faldum A, Zwiener I, Warmuth-Metz M, Pietsch T, Pohl F, Sörensen N, Calaminus G; Study Committee of KRANIOPHARYNGEOM 2000. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol. 2011;165:17-24. Epub 2011 Apr 13
Caldarelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C. Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Childs Nerv Syst. 2005;21:747-757. Epub 2005 Jul 2
Hoffmann A, Brentrup A, Müller HL. First report on spinal metastasis in childhood-onset craniopharyngioma. J Neurooncol. 2016;129:193-194. Epub 2016 Jun 9
Müller HL. Paediatrics: surgical strategy and quality of life in craniopharyngioma. Nat Rev Endocrinol. 2013;9:447-449. Epub 2013 Jun 25
Yousuf OK, Salehani A, Zimmerman K, Estevez-Ordonez D, Madura C, Arynchyna-Smith A, Johnston JM, Rozzelle CJ, Rocque BG, Blount JP. Does subtotal resection ameliorate hypothalamic morbidity in pediatric craniopharyngioma? A 30-year retrospective cohort study. J Neurosurg Pediatr. 2023;32:569-575.
Sarkar S, Chacko SR, Korula S, Simon A, Mathai S, Chacko G, Chacko AG. Long-term outcomes following maximal safe resection in a contemporary series of childhood craniopharyngiomas. Acta Neurochir (Wien). 2021;163:499-509. Epub 2020 Oct 19
Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N, Zerah M, Bezerra M, Renier D, Pierre-Kahn A, Sainte-Rose C. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg. 2007;106(1 Suppl):3-12.
Gautier A, Godbout A, Grosheny C, Tejedor I, Coudert M, Courtillot C, Jublanc C, De Kerdanet M, Poirier JY, Riffaud L, Sainte-Rose C, Van Effenterre R, Brassier G, Bonnet F, Touraine P; Craniopharyngioma Study Group. Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients. J Clin Endocrinol Metab. 2012;97:1258-1267. Epub 2012 Feb 8
Crotty TB, Scheithauer BW, Young WF Jr, Davis DH, Shaw EG, Miller GM, Burger PC. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg. 1995;83:206-214.
Borrill R, Cheesman E, Stivaros S, Kamaly-Asl ID, Gnanalingham K, Kilday JP. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. Childs Nerv Syst. 2019;35:169-173. Epub 2018 Aug 1
Gan HW, Morillon P, Albanese A, Aquilina K, Chandler C, Chang YC, Drimtzias E, Farndon S, Jacques TS, Korbonits M, Kuczynski A, Limond J, Robinson L, Simmons I, Thomas N, Thomas S, Thorp N, Vargha-Khadem F, Warren D, Zebian B, Mallucci C, Spoudeas HA. National UK guidelines for the management of paediatric craniopharyngioma. Lancet Diabetes Endocrinol. 2023;11:694-706.
Holmer H, Ekman B, Björk J, Nordstöm CH, Popovic V, Siversson A, Erfurth EM. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy. Eur J Endocrinol. 2009;161:671-679. Epub 2009 Aug 10
Wijnen M, van den Heuvel-Eibrink MM, Janssen JAMJL, Catsman-Berrevoets CE, Michiels EMC, van Veelen-Vincent MC, Dallenga AHG, van den Berge JH, van Rij CM, van der Lely AJ, Neggers SJCMM. Very long-term sequelae of craniopharyngioma. Eur J Endocrinol. 2017;176:755-767. Epub 2017 Mar 21
Losa M, Castellino L, Pagnano A, Rossini A, Mortini P, Lanzi R. Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence. J Clin Endocrinol Metab. 2020;105:1573-1580.
Olsson DS, Buchfelder M, Wiendieck K, Kremenevskaja N, Bengtsson BÅ, Jakobsson KE, Jarfelt M, Johannsson G, Nilsson AG. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur J Endocrinol. 2012;166:1061-1068. Epub 2012 Mar 28


